$891 Million is the total value of Omega Fund Management, LLC's 26 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 13.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NUVB | Nuvation Bio | $280,431,000 | +6.8% | 28,212,376 | 0.0% | 31.46% | +5.8% | |
| REPL | Sell | Replimune Group | $145,120,000 | -24.6% | 4,896,074 | -2.2% | 16.28% | -25.2% |
| KRON | Kronos Bio | $80,031,000 | -12.5% | 3,818,283 | 0.0% | 8.98% | -13.3% | |
| MORF | Sell | Morphic Holding | $74,536,000 | -26.5% | 1,315,952 | -25.5% | 8.36% | -27.2% |
| New | Imago Biosciences | $60,465,000 | – | 3,018,737 | +100.0% | 6.78% | – | |
| GOSS | Gossamer Bio | $41,740,000 | +54.8% | 3,320,608 | 0.0% | 4.68% | +53.4% | |
| IKNA | Ikena Oncology | $28,384,000 | -10.1% | 2,249,123 | 0.0% | 3.18% | -10.9% | |
| New | Adagio Therapeutics | $26,732,000 | – | 632,855 | +100.0% | 3.00% | – | |
| ALPN | Buy | Alpine Immune Sciences | $21,656,000 | +87.3% | 2,029,580 | +58.0% | 2.43% | +85.6% |
| SANA | Sana Biotechnology, Inc. | $19,001,000 | +14.5% | 843,750 | 0.0% | 2.13% | +13.6% | |
| IMUX | Immunic Inc | $15,825,000 | -27.8% | 1,788,160 | 0.0% | 1.78% | -28.5% | |
| ARQT | Arcutis Biothereapeutics | $14,903,000 | -12.5% | 623,836 | 0.0% | 1.67% | -13.2% | |
| SPRB | Spruce Biosciences | $12,988,000 | -46.4% | 2,161,022 | 0.0% | 1.46% | -46.9% | |
| PRTK | Buy | Paratek Pharmaceuticals | $12,669,000 | -28.6% | 2,606,809 | +0.2% | 1.42% | -29.2% |
| New | Icosavax | $12,617,000 | – | 426,395 | +100.0% | 1.42% | – | |
| SYRS | Buy | Syros Pharmaceuticals | $11,232,000 | -9.4% | 2,512,705 | +10.5% | 1.26% | -10.2% |
| AVIR | Sell | Atea Pharmaceuticals | $5,770,000 | -64.0% | 164,577 | -78.0% | 0.65% | -64.4% |
| CMPI | Checkmate Pharmaceuticals | $5,300,000 | -33.4% | 1,335,050 | 0.0% | 0.60% | -34.0% | |
| OMEG | Omega Alpha SPAC | $4,877,000 | -2.2% | 501,000 | 0.0% | 0.55% | -3.0% | |
| CDTX | Cidara Therapeutics | $4,492,000 | +10.9% | 2,005,249 | 0.0% | 0.50% | +10.0% | |
| OBSV | ObsEva SA | $3,108,000 | +2.6% | 999,364 | 0.0% | 0.35% | +1.7% | |
| EPIX | ESSA Pharma | $2,626,000 | -72.0% | 328,196 | 0.0% | 0.30% | -72.2% | |
| JNCE | Jounce Therapeutics | $2,047,000 | +9.3% | 275,513 | 0.0% | 0.23% | +8.5% | |
| IMCR | Immunocore Holdings | $1,910,000 | -5.1% | 51,535 | 0.0% | 0.21% | -6.1% | |
| TRVI | Trevi Therapeutics | $1,769,000 | -37.8% | 1,263,408 | 0.0% | 0.20% | -38.5% | |
| FGEN | FibroGen Inc | $1,150,000 | -66.9% | 130,646 | 0.0% | 0.13% | -67.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Paratek Pharmaceuticals, Inc. | 34 | Q1 2023 | 39.1% |
| FibroGen, Inc. | 28 | Q3 2021 | 14.3% |
| Jounce Therapeutics | 25 | Q1 2023 | 11.6% |
| Pieris Pharmaceuticals | 23 | Q1 2021 | 5.2% |
| Replimune Group | 21 | Q3 2023 | 47.2% |
| Cidara Therapeutics | 20 | Q3 2021 | 5.8% |
| Morphic Holding | 18 | Q3 2023 | 22.0% |
| Immunic Inc | 18 | Q3 2023 | 9.0% |
| Dicerna Pharmaceuticals | 18 | Q1 2019 | 3.7% |
| Egalet | 17 | Q4 2018 | 19.6% |
View Omega Fund Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| 13F-HR/A | 2021-11-15 |
View Omega Fund Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.